August 31, 2017 / 8:14 PM / in 3 months

BRIEF-Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

Aug 31 (Reuters) - Progenics Pharmaceuticals Inc

* Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

* Progenics - co was notified that commercial drug product manufacturing facility for Azedra needs more time to prepare for pre-approval inspection by FDA

* Progenics Pharma - ‍data from pivotal phase 2b study of azedra will be presented at 5th International Symposium On Pheochromocytoma & Paraganglioma on Sept. 1

* Progenics - ‍under rolling submission, co has submitted all portions of NDA to FDA, except for notification of pre-approval inspection readiness​

* Progenics Pharmaceuticals Inc - ‍interactions with FDA on Azedra rolling submission continue to be “positive and productive”​

* Progenics Pharmaceuticals - ‍manufacturer has indicated it will need up to a few months to complete preparation for pre-approval inspection​ by FDA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below